BioCryst announced that its flu drug, peramivir was not significantly successful in improving flu symptoms, as compared to Placebo. The mid-stage trial saw some improvement in the patients; however, the results were not statistically significant. Analysts do not expect the late-stage trials to be effective. This news, along with a downgrade from analysts led to a sharp decrease in the company’s stock price.